Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor in adults. Despite standard treatments, the prognosis remains extremely poor, highlighting the urgent need for innovative therapeutic strategies.
Clinique Neuro Outaouais (CNO) is committed to advancing GBM care through clinical research. We initiated and conducted a clinical trial investigating the addition of Avelumab, an immune checkpoint inhibitor, to conventional GBM therapies, exploring whether immunotherapy can enhance outcomes.
Presently, CNO is actively studying the potential of non-invasive neuromodulation using repetitive transcranial magnetic stimulation (rTMS) as a supportive intervention in GBM patients.
CLINICAL TRIALS
Studies Recruiting
Please inquire at the time of writing there is no recruiting study.
Studies Ongoing
CNO is exploring through a pilot trial the impact of rTMS on GBM.
Studies Completed
2017: Avelumab in patients with newly diagnosed GBM (Phase II).
Completed
2017: Avelumab in patients with newly diagnosed GBM (Phase II)
